Cargando…
Sex Differences in Lung Cancer Treatment and Outcomes at a Large Hybrid Academic-Community Practice
INTRODUCTION: Lung cancer is the leading cause of cancer-related death and the second most often diagnosed malignancy worldwide. Males have higher incidence of lung cancer and higher mortality. It is hypothesized that the sex differences in survival are primarily driven by a better response of femal...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983352/ https://www.ncbi.nlm.nih.gov/pubmed/35400080 http://dx.doi.org/10.1016/j.jtocrr.2022.100307 |
_version_ | 1784681968369139712 |
---|---|
author | Stabellini, Nickolas Bruno, Debora S. Dmukauskas, Mantas Barda, Amie J. Cao, Lifen Shanahan, John Waite, Kristin Montero, Alberto J. Barnholtz-Sloan, Jill S. |
author_facet | Stabellini, Nickolas Bruno, Debora S. Dmukauskas, Mantas Barda, Amie J. Cao, Lifen Shanahan, John Waite, Kristin Montero, Alberto J. Barnholtz-Sloan, Jill S. |
author_sort | Stabellini, Nickolas |
collection | PubMed |
description | INTRODUCTION: Lung cancer is the leading cause of cancer-related death and the second most often diagnosed malignancy worldwide. Males have higher incidence of lung cancer and higher mortality. It is hypothesized that the sex differences in survival are primarily driven by a better response of females to treatment. The primary objective of this work is to analyze and describe outcome differences between males and females diagnosed with having lung cancer. METHODS: Data were obtained from a large hybrid academic-community practice institution and validated with Surveillance, Epidemiology, and End Results (SEER). The initial cohort included patients aged more than or equal to 18 years diagnosed with having primary malignant lung cancer. Patients were excluded from the analysis if they had an unknown diagnosis date, were missing sex, or had prior history of cancer. Chi-square, t test, and Kruskal-Wallis tests were used to compare characteristics of males and females. Risks were estimated by logistic and Cox regressions. RESULTS: A total of 8909 patients from our institution and 725,018 in SEER were analyzed. Male-to-female ratio was 1.0. Females were more likely to undergo surgery and less likely to be treated with immunotherapy. Females had higher rates of documented psychological affections, depression, anxiety, urinary tract infection, hypothyroidism, and hyperthyroidism, while displaying lower rates of acute kidney injury, myocardial infarction, and myocarditis. Paired multivariable models revealed a lower risk of death for females in SEER (hazard ratio for females = 0.84, confidence interval: 0.69–1.02, p = 0.08) and equal risks in our institution (hazard ratio for females = 0.84, confidence interval: 0.69–1.02, p = 0.08). CONCLUSIONS: Female sex was associated with higher surgical rates, lower immunotherapy use rates, higher rates of endocrinologic complications after immunotherapy use, and higher rates of psychological disorders. |
format | Online Article Text |
id | pubmed-8983352 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-89833522022-04-07 Sex Differences in Lung Cancer Treatment and Outcomes at a Large Hybrid Academic-Community Practice Stabellini, Nickolas Bruno, Debora S. Dmukauskas, Mantas Barda, Amie J. Cao, Lifen Shanahan, John Waite, Kristin Montero, Alberto J. Barnholtz-Sloan, Jill S. JTO Clin Res Rep Original Article INTRODUCTION: Lung cancer is the leading cause of cancer-related death and the second most often diagnosed malignancy worldwide. Males have higher incidence of lung cancer and higher mortality. It is hypothesized that the sex differences in survival are primarily driven by a better response of females to treatment. The primary objective of this work is to analyze and describe outcome differences between males and females diagnosed with having lung cancer. METHODS: Data were obtained from a large hybrid academic-community practice institution and validated with Surveillance, Epidemiology, and End Results (SEER). The initial cohort included patients aged more than or equal to 18 years diagnosed with having primary malignant lung cancer. Patients were excluded from the analysis if they had an unknown diagnosis date, were missing sex, or had prior history of cancer. Chi-square, t test, and Kruskal-Wallis tests were used to compare characteristics of males and females. Risks were estimated by logistic and Cox regressions. RESULTS: A total of 8909 patients from our institution and 725,018 in SEER were analyzed. Male-to-female ratio was 1.0. Females were more likely to undergo surgery and less likely to be treated with immunotherapy. Females had higher rates of documented psychological affections, depression, anxiety, urinary tract infection, hypothyroidism, and hyperthyroidism, while displaying lower rates of acute kidney injury, myocardial infarction, and myocarditis. Paired multivariable models revealed a lower risk of death for females in SEER (hazard ratio for females = 0.84, confidence interval: 0.69–1.02, p = 0.08) and equal risks in our institution (hazard ratio for females = 0.84, confidence interval: 0.69–1.02, p = 0.08). CONCLUSIONS: Female sex was associated with higher surgical rates, lower immunotherapy use rates, higher rates of endocrinologic complications after immunotherapy use, and higher rates of psychological disorders. Elsevier 2022-03-09 /pmc/articles/PMC8983352/ /pubmed/35400080 http://dx.doi.org/10.1016/j.jtocrr.2022.100307 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Stabellini, Nickolas Bruno, Debora S. Dmukauskas, Mantas Barda, Amie J. Cao, Lifen Shanahan, John Waite, Kristin Montero, Alberto J. Barnholtz-Sloan, Jill S. Sex Differences in Lung Cancer Treatment and Outcomes at a Large Hybrid Academic-Community Practice |
title | Sex Differences in Lung Cancer Treatment and Outcomes at a Large Hybrid Academic-Community Practice |
title_full | Sex Differences in Lung Cancer Treatment and Outcomes at a Large Hybrid Academic-Community Practice |
title_fullStr | Sex Differences in Lung Cancer Treatment and Outcomes at a Large Hybrid Academic-Community Practice |
title_full_unstemmed | Sex Differences in Lung Cancer Treatment and Outcomes at a Large Hybrid Academic-Community Practice |
title_short | Sex Differences in Lung Cancer Treatment and Outcomes at a Large Hybrid Academic-Community Practice |
title_sort | sex differences in lung cancer treatment and outcomes at a large hybrid academic-community practice |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983352/ https://www.ncbi.nlm.nih.gov/pubmed/35400080 http://dx.doi.org/10.1016/j.jtocrr.2022.100307 |
work_keys_str_mv | AT stabellininickolas sexdifferencesinlungcancertreatmentandoutcomesatalargehybridacademiccommunitypractice AT brunodeboras sexdifferencesinlungcancertreatmentandoutcomesatalargehybridacademiccommunitypractice AT dmukauskasmantas sexdifferencesinlungcancertreatmentandoutcomesatalargehybridacademiccommunitypractice AT bardaamiej sexdifferencesinlungcancertreatmentandoutcomesatalargehybridacademiccommunitypractice AT caolifen sexdifferencesinlungcancertreatmentandoutcomesatalargehybridacademiccommunitypractice AT shanahanjohn sexdifferencesinlungcancertreatmentandoutcomesatalargehybridacademiccommunitypractice AT waitekristin sexdifferencesinlungcancertreatmentandoutcomesatalargehybridacademiccommunitypractice AT monteroalbertoj sexdifferencesinlungcancertreatmentandoutcomesatalargehybridacademiccommunitypractice AT barnholtzsloanjills sexdifferencesinlungcancertreatmentandoutcomesatalargehybridacademiccommunitypractice |